Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Bumble Inc (BMBL) Price & Performance

AbCellera Biologics IncTrade
Bumble IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Bumble Inc — how do they compare? AbCellera Biologics Inc trades at $10.11 (market cap $2.99B), while Bumble Inc trades at $2.6 (market cap $366.87M). The key difference: AbCellera Biologics Inc is far larger — about 8.2× Bumble Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

ABCLBMBL
Market Cap
$2.99B$366.87M
Sector
HealthTechnology
52-Week High
$9.76$7.17
52-Week Low
$2.78$2.70
Enterprise Value
$2.58B$672.73M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Bumble Inc

Bumble (BMBL) trades at $2.62, down 4.03% on the day, reflecting ongoing investor concerns. The stock is in a bearish technical trend with negative earnings and declining revenue. Recent strategic shifts, including removing the women-first messaging rule and exploring a sale, aim to revive growth amid falling paying users. Valuation ratios like P/S of 0.38 and P/B of 0.71 appear low, but profitability remains weak with a net income margin of -57.96%.

The outlook is cautious; while cost controls and product changes could stabilize the business, persistent losses and competitive pressures pose significant risks. Analyst consensus is mixed with a $3.62 price target, but high institutional selling and bearish sentiment suggest limited near-term upside. Investors should weigh potential turnaround against execution risks and market skepticism.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL